CA2216700C - Compositions pharmaceutiques a effet synergique a base d'acetonide de triamcinolone et de halcinonide - Google Patents
Compositions pharmaceutiques a effet synergique a base d'acetonide de triamcinolone et de halcinonide Download PDFInfo
- Publication number
- CA2216700C CA2216700C CA002216700A CA2216700A CA2216700C CA 2216700 C CA2216700 C CA 2216700C CA 002216700 A CA002216700 A CA 002216700A CA 2216700 A CA2216700 A CA 2216700A CA 2216700 C CA2216700 C CA 2216700C
- Authority
- CA
- Canada
- Prior art keywords
- treatment
- halcinonide
- triamcinolone acetonide
- psoriasis
- figures
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 title claims abstract description 30
- 229960002383 halcinonide Drugs 0.000 title claims abstract description 30
- 229960002117 triamcinolone acetonide Drugs 0.000 title claims abstract description 28
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 title claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 230000002195 synergetic effect Effects 0.000 title description 9
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 40
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 28
- 239000004480 active ingredient Substances 0.000 claims abstract description 26
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 20
- 239000003937 drug carrier Substances 0.000 claims abstract description 13
- 239000011885 synergistic combination Substances 0.000 claims abstract description 10
- 241001303601 Rosacea Species 0.000 abstract description 5
- 201000004700 rosacea Diseases 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 description 62
- 239000006071 cream Substances 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 11
- 230000003902 lesion Effects 0.000 description 11
- 208000003251 Pruritus Diseases 0.000 description 9
- 208000010201 Exanthema Diseases 0.000 description 8
- 201000005884 exanthem Diseases 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 206010037844 rash Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000002414 leg Anatomy 0.000 description 7
- 208000017520 skin disease Diseases 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 206010039509 Scab Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 230000035515 penetration Effects 0.000 description 5
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 4
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 4
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 229960004544 cortisone Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 206010012434 Dermatitis allergic Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 206010021531 Impetigo Diseases 0.000 description 2
- 201000009053 Neurodermatitis Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 210000001513 elbow Anatomy 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- -1 methylenedioxy steroids Chemical class 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030012 Occupational dermatitis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000036002 Rash generalised Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 206010041955 Stasis dermatitis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 235000008960 ketchup Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000000325 methylidene group Chemical class [H]C([H])=* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 150000003128 pregnanes Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- RJKFOVLPORLFTN-UHFFFAOYSA-N progesterone acetate Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 RJKFOVLPORLFTN-UHFFFAOYSA-N 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000003779 seborrheic infantile dermatitis Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Une composition pharmaceutique est constituée d'une association synergique contenant, comme principes actifs, au moins environ 0,01 % en poids d'acétonide de triamcinolone et au moins environ 0,01 % en poids de halcinonide, en association avec un excipient pharmaceutiquement acceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1995/009544 WO1996003132A1 (fr) | 1994-07-28 | 1995-07-27 | Compositions pharmaceutiques a effet synergique a base d'acetonide de triamcinolone et de halcinonide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2216700A1 CA2216700A1 (fr) | 1996-02-08 |
| CA2216700C true CA2216700C (fr) | 2002-09-17 |
Family
ID=22249542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002216700A Expired - Fee Related CA2216700C (fr) | 1995-07-27 | 1995-07-27 | Compositions pharmaceutiques a effet synergique a base d'acetonide de triamcinolone et de halcinonide |
Country Status (3)
| Country | Link |
|---|---|
| CA (1) | CA2216700C (fr) |
| DE (1) | DE69506288T2 (fr) |
| DK (1) | DK0840613T3 (fr) |
-
1995
- 1995-07-27 CA CA002216700A patent/CA2216700C/fr not_active Expired - Fee Related
- 1995-07-27 DK DK95929328T patent/DK0840613T3/da active
- 1995-07-27 DE DE69506288T patent/DE69506288T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2216700A1 (fr) | 1996-02-08 |
| DE69506288T2 (de) | 1999-06-24 |
| DK0840613T3 (da) | 2000-08-28 |
| DE69506288D1 (de) | 1999-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0840613B1 (fr) | Compositions pharmaceutiques a effet synergique a base d'acetonide de triamcinolone et de halcinonide | |
| IL95820A (en) | Preparations for the treatment of inflammatory or allergic painful physical defects containing SIC-8-methyl-N- and anilyl-6-nonanamide | |
| CA2408541C (fr) | Traitement contre l'eczema et/ou le psoriasis | |
| US6613800B1 (en) | Method and compositions for treating psoriasis, eczema, seborrhea and arthritis | |
| EP0908183A1 (fr) | Déhydroépiandrostérone ou ses dérivés pour augmenter la quantité d'acide hyaluronique dans la peau | |
| AU2001260833A1 (en) | Treating eczema and/or psoriasis | |
| US8586064B2 (en) | Treating eczema and/or psoriasis | |
| US4119713A (en) | Analgesic and anti-inflammatory composition | |
| US20050152993A1 (en) | Composition for and method of treatment for skin ailments | |
| CA2216700C (fr) | Compositions pharmaceutiques a effet synergique a base d'acetonide de triamcinolone et de halcinonide | |
| JPH03227921A (ja) | ケロイド治療剤 | |
| GB2079151A (en) | Medication for relief of intra-articular and intra-muscular discomfort | |
| EP0916341A2 (fr) | Compositions pharmaceutiques à effet synergique à base d'acétonide de triamcinolone et de halcinonide | |
| AU701833B2 (en) | Psoriasis treatment | |
| US20040204492A1 (en) | Topical composition and method for treating seborrheic dermatitis | |
| WO1992003142A1 (fr) | Composition destinee au traitement topique du psoriasis | |
| AU2011269256B2 (en) | Agent for the treatment of skin conditions | |
| WO1994005301A1 (fr) | Compositions destinees au traitement de la dermite, contenant du soufre, de l'acide salicylique et du dimethylsulfone | |
| JP2024048695A (ja) | 皮膚炎治療用の外用組成物 | |
| NZ522434A (en) | Treating eczema and/or psoriasis | |
| HK1008814B (en) | Ointments comprising mometasone furoate and salicylic acid for the topical treatment of psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20130729 |